Avatrombopag (Sucoxin) Instructions

Avatrombopag is indicated for the treatment of severe thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo invasive procedures. Avatrombopag is indicated for the treatment of primary chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments (eg, corticosteroids, immunoglobulins).

Mechanism of action: Avatrombopag is an orally bioavailable small molecule thrombopoietin (TPO) receptor agonist that stimulates the proliferation and differentiation of megakaryocytes and bone marrow progenitor cells, thereby increasing platelet production. Avatrombopag does not compete with thrombopoietin for binding to the TPO receptor and has additive pharmacological effects with TPO on platelet production. Avatrombopag is a thrombopoietin receptor (TPOR; MPL) agonist with possible megakaryopoiesis-stimulating activity. After administration, avatrombopag binds to and stimulates the platelet thromboxane receptor (TPOR), which causes megakaryocytes to proliferate and differentiate from myeloid progenitor cells. This process increases platelet production and may help prevent chemotherapy-induced thrombocytopenia (CIT). TPOR is classified as a cytokine receptor and is a member of the hematopoietic receptor superfamily.

Dosage: Avatrombopag is usually taken by mouth once daily with food. Your dose may vary depending on your condition, platelet levels, and other medications you take.

Chronic liver disease: You will start taking your medication 10 to 13 days before your scheduled surgery Typical dosage is 40 mg (2 tablets) or 60 mg (3 tablets) taken once daily with food for 5 days. You will have your last dose 5 to 8 days before surgery.

Chronic immune thrombocytopenia (ITP): The typical starting dose is 20 mg tablet (1 tablet) taken orally once daily with a meal. The maximum dose is 40 mg once daily. Your provider may adjust your dose based on your platelet levels.

Side Effects: If you have signs of an allergic reaction during treatment with avatrombopag: Hives; trouble breathing; swelling of the face, lips, tongue, or throat, get emergency medical help.

Blood clots may form while using avatrombopag. Call your doctor or get emergency medical help if you have: chest pain, shortness of breath; fast heartbeat; pain, swelling, or redness in one or both legs; stomach pain or tenderness; sudden fever or chills, yellowing of the skin or eyes; or bloody or tarry stools, coughing up blood, or vomit that looks like coffee grounds.

Common side effects of avatrombopag may include:: fever; easy bruising or bleeding (nosebleeds and bleeding gums); purple or red spots on the skin; feeling tired; headache, joint pain; cold symptoms such as runny or stuffy nose, sneezing, sore throat; nausea, stomach pain; or swelling of the hands or feet. This is not a complete list of side effects. Other side effects may occur, and patients should seek medical attention immediately if they experience any discomfort while taking avatrombopag.

Storage: Store20°C to 25°C (68°F to 77°F), movement allowed between 15°C to 30°C (59°F to 86°F). Store avatrombopag tablets in their original packaging.